Themed Issue – Patient and Public Involvement in
Health Economics Research (HEOR)
The disability movement first coined the phrase “Nothing about us without us” in the 1990s. Since then, the idea has widened and public and patient involvement (PPI) in health research has grown to be the norm. Patients and the public are no longer merely subjects or recipients of health economics and outcomes research (HEOR), we are now engaging with them as active research partners and collaborators, including as co-investigators and co-authors.
The Patient invites the submission of papers (original research, reviews and commentaries) on the role of patients and the general public in HEOR for a themed issue of the journal to be published in early 2020, guest edited by Paula Lorgelly (King’s College London).
We encourage papers that highlight innovative ways researchers have engaged patients and/or the public, projects that have trained patients/the public in order to increase their understanding of HEOR, and papers that have measured and quantified the value of patient/public engagement to their project. Country-specific perspectives are also encouraged particularly given that different funding bodies have varying requirements and standards regarding PPI. Papers can be either methodological or applied. Article types can be original research, thought pieces or reviews.
Topics of interest include:
- Patients and the public as collaborators, including generating research questions
- Patients and the public as trialists or modellers, i.e. designing methods
- Training patients and the public to increase/improve their value to projects
- Comparison of different engagement approaches, including PPI in HEOR projects vs other types of studies
- Comparisons of projects involving patients versus those involving the public
- Lay patients vs professional patients
- The role of patient groups and/or research charities
- PPI and conflicts of interest
- Risks and benefits of greater PPI in HEOR
Note we are specifically interested in the role of patients and the public in HEOR; papers either on PPI in funding decisions (for research funding or technology adoption) or on outcome measures that are not preference based or use patient values while of interest to the journal are outside of the scope of this themed issue.
Please submit an abstract describing your proposed paper by 31st August 2019 to email@example.com. Full papers will be invited by 30th September 2019 and manuscripts due early 2020.
This was the subject of many discussions at the recent World Drug Safety Congress Americas 2019 in Philadelphia. As has been the case at many pharmacovigilance meetings in the last few years, artificial intelligence, outsourcing solutions and automation were hot topics, with debates over the future use of such strategies to achieve operational efficiency whilst strengthening patient safety. Continue reading “Safety strategies and efficiencies – what is the best solution?”
In March 2019, the small molecule brexanolone was approved by the United States Food and Drug Administration (FDA) for the treatment of postpartum depression (PPD) in adult women. Brexanolone, developed by Sage Therapeutics under a license from the University of California, was granted priority review status and breakthrough therapy designation by the FDA. Continue reading “Brexanolone (Zulresso™): First Global Approval – First approved therapy for postpartum depression”
I recently attended the 7th DIA India Pharmacovigilance (PV) Conference in Mumbai. One of the sessions was dedicated to the Impact of Artificial Intelligence (AI) and Predictive Sciences in the world of PV. The session was moderated by Moin Don and Anju Agarwal; the panel comprised Mengesh Kulkarni, Saikat Biswas, Retesh Kumar and Saurahb Khurana.
The interaction between the panel of guest speakers and the open floor reminded me of the Mumbai traffic: it was frenetic, loud, comprised of many different thought vehicles and yet despite all this – it traveled in the same direction without any head-on collisions! Continue reading “Artificial Intelligence: organised chaos or chaos ordered?”
It is likely that in one’s lifetime a friend or family member will be diagnosed with Alzheimer’s disease. As of 2018, approximately 50 million people worldwide are living with dementia and this number is expected to triple to 152 million by 2050.
Despite the increasing prevalence of the disease, no new drugs have been approved for the treatment of Alzheimer’s since 2003. An article recently published on PharmaTimes proclaims, “The search for a cure for Alzheimer’s is far from over.”
Continue reading “Is the Search for a Cure for Alzheimer’s Disease Hopeless?”
This first session of the conference, chaired by J Vijay Venkatraman, gave the audience a broad overview of the state of flux in pharmacovigilance, essentially resulting from changes initiated in Europe – the impact of evolving Eudrovigilance, Brexit and E2B R3 were the focal points. Continue reading “DIA India 2019: Regulatory Trends in Clinical Safety & Pharmacovigilance (An EU perspective).”
It may not have been his outright intention, but Dr Y.K. Gupta certainly set the scene and piqued the interest of the eager audience ready to receive information regarding multiple aspects of pharmacovigilance that would be lively debated throughout the following two days. Continue reading “DIA India 2019 – Keynote Presentation: India Implements Initiatives to Encourage Domestic Clinical Trial Activity and Increase Safety”
The theme for this SEVENTH Indian conference was…
“transforming clinical safety and pharmacovigilance”
Continue reading “DIA India: 7th Pharmacovigilance Conference 2019”
In December 2018, roxadustat, developed by FibroGen, in collaboration with Astellas and AstraZeneca, received its first global approval in China for the treatment of anaemia in patients with dialysis-dependent chronic kidney disease (DD-CKD). Roxadustat is expected to launch in China in the second half of 2019.
Continue reading “Roxadustat (Ai Rui Zhuo® in China): First Global Approval – First-in-class small molecule for anaemia in patients with DD-CKD”
The recent first global approval of tagraxofusp (Elzonris™) has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs, based on the development milestones tracked in AdisInsight.
In December 2018, tagraxofusp, developed by Stemline Therapeutics, was approved by the United States Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and children 2 years and older. Continue reading “Tagraxofusp (Elzonris™): First Global Approval – Breakthrough therapy for BPDCN and novel CD123-targeted therapy”